- Home
- Companies
- Auspex Diagnostics
- Articles
Auspex Diagnostics articles
Background
Combination chemotherapy using fluorouracil, leucovorin with or without oxaliplatin (5-FU and FOLFOX) are standard treatment for locally advanced colon cancer. However, about half of the patients developed recurrence. The objective of this study was to use gene profiling to predict treatment efficacy for colon cancer patients (stages 1-3). We developed three prediction models: the first determines the likelihood of recurrence after curative resection while
Jeng-Kai Jiang;Hung-Shin Lin;Jen-Kou Lin;Yu-Chung Wu;Teh-Ying Chou;Nien Wei
Abstract
Background: Five-year survival for stage I-II lung cancer is quite low even after complete surgical resection. Current guidelines recommend adjuvant treatment only for selected patients with stage II or higher disease. A prediction model that identifies patients at high risk of recurrence who may benefit from adjuvant treatment is greatly needed. Many existing prediction models include a small number of genes that were found to be significant
Natalie Lui;Nien Wei;Winston Trope;Shannon Nesbit
Abstract
Background
Cancer genomic signatures may vary using different platforms. We compared the differential gene expression in non-small cell lung cancer (NSCLC) between two platforms in order to find the most relevant genomic signatures of tumor recurrence.
Materials and Methods
We analyzed gene expression in frozen lung cancer tissue from 59 selected patients who had undergone surgical resection of NSCLC.
Chang JW1;wei nancy;Huang JL;Wang TH
Abstract
We developed a series of models to predict the likelihood of recurrence and the response to chemotherapy for the personalized treatment of stage I and II colorectal cancer patients. A recurrence prediction model was developed from 235 stage I/II patients. The model successfully distinguished between high-risk and low-risk groups, with a hazard ratio of recurrence of 4.66 (p < 0.0001). More importantly, the model was accurate for
JHung-Hsin Lin;Nien-Chih Wei;Teh-Ying Chou;Chun-Chi Lin;Yuan-Tsu Lan;Shin-Ching Chang
Purpose
The incidence and mortality rates of cervical cancer are declining in the United States; however, worldwide, cervical cancer is still one of the leading causes of death in women, second only to breast cancer. This disparity is at least partially explained by the absence of or comparatively ineffective screening programs in the developing world. Recent advances in expression genomics have enabled the use of DNA microarray to profile gene expression of various c
Yick Wong;Zachariah E;Nien Wei;Joseph Porter;Ragini Vittal;Rong Huang;Yong Lin;Jason Liao
